Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 11, Issue 5, Pages 667-677
Publisher
Informa Healthcare
Online
2011-04-04
DOI
10.1517/14712598.2011.573624
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
- (2010) Dominique Descamps et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Mechanism of action of clinically approved adjuvants
- (2009) Bart N Lambrecht et al. CURRENT OPINION IN IMMUNOLOGY
- Follicular Helper T Cells: Lineage and Location
- (2009) Nicolas Fazilleau et al. IMMUNITY
- AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
- (2009) A. M. Didierlaurent et al. JOURNAL OF IMMUNOLOGY
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
- (2009) Darron R. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding
- (2009) Nicolas Fazilleau et al. NATURE IMMUNOLOGY
- Mechanism of action of licensed vaccine adjuvants
- (2009) Elaine Tritto et al. VACCINE
- Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
- (2008) C. R. Casella et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention
- (2008) David Jenkins GYNECOLOGIC ONCOLOGY
- Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
- (2008) Tino F. Schwarz et al. GYNECOLOGIC ONCOLOGY
- Vaccine Adjuvants Alter TCR-Based Selection Thresholds
- (2008) Laurent Malherbe et al. IMMUNITY
- Inflammatory signals in dendritic cell activation and the induction of adaptive immunity
- (2008) Olivier Joffre et al. IMMUNOLOGICAL REVIEWS
- Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
- (2008) Mirjam Kool et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
- (2008) Stephanie C. Eisenbarth et al. NATURE
- New horizons in adjuvants for vaccine development
- (2008) Steven G. Reed et al. TRENDS IN IMMUNOLOGY
- Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia
- (2008) F. Xavier Bosch et al. VACCINE
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
- (2008) Thomas Verstraeten et al. VACCINE
- Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
- (2008) Tino F. Schwarz et al. VACCINE
- Antigen presentation by monocytes and monocyte-derived cells
- (2007) Gwendalyn J Randolph et al. CURRENT OPINION IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started